Humacyte Reports Q2 2026 Financials, Advances Clinical Trials
In the second quarter of 2026, Humacyte (HUMA) reported product revenue of $0.4 million from its commercial launch of Symvess, a significant increase compared to $0.1 million in the prior period. The company also shared positive interim results for its V012 Phase III trial: patients receiving acellular tissue-engineered vessels experienced 91 more catheter-free days than those with AV fistulas (p-value = 0.0007), along with a notable reduction in infection rates. Humacyte plans to file a supplemental Biologics License Application for dialysis access by November 2026, aiming for an end-of-Q2-2027 launch if granted priority review. The company also announced the initiation of its Phase IIa study on coronary artery bypass grafting in Q3 2026 after FDA acceptance of its IND application. Financially, Humacyte reported a net loss of $36.8 million for Q2 and $54.4 million for H1-2026 due to R&D expenses and non-cash liabilities. The company raised $57.5 million in June 2026 through an equity offering and currently holds $80.3 million in cash, supporting ongoing operations.
Tickers: $HUMA
Topics: capital_raise clinical_trial fda_submission revenue_growth